npj Breast Cancer

Papers
(The median citation count of npj Breast Cancer is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers420
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer208
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab179
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer160
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer147
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?110
International survey on invasive lobular breast cancer identifies priority research questions107
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab103
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients96
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women85
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer80
Biological correlates associated with high-risk breast cancer patients identified using a computational method78
Immunotherapy for early triple negative breast cancer: research agenda for the next decade78
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells72
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors70
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment69
Breastfeeding attributable fraction of triple negative breast cancer in the US64
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)62
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer57
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events56
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models54
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer51
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer50
Temporal evolution of breast cancer brain metastases treatments and outcomes49
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial46
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer46
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice45
Survival outcomes after omission of surgery for ductal carcinoma in situ44
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)44
Circulating tumor DNA validity and potential uses in metastatic breast cancer42
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays39
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC38
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions38
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer38
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases38
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis37
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines37
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer36
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer36
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature34
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors33
Kataegis in clinical and molecular subgroups of primary breast cancer32
Understanding metastasis mixed-treatment responses through genomic analyses32
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center32
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification31
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer31
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling31
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment30
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models29
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201629
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment29
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer29
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance29
Is conservative management of ductal carcinoma in situ risky?29
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer28
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program28
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies27
Oncogene-mediated metabolic gene signature predicts breast cancer outcome27
Large language model (ChatGPT) as a support tool for breast tumor board26
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer26
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin26
Cook and Move for Your Life, an eHealth intervention for women with breast cancer25
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer25
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer25
A systematic review of determinants of breast cancer risk among women with benign breast disease25
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study24
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer24
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy24
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial24
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies23
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief23
Prognostic value of structural variants in early breast cancer patients22
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer22
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models22
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers21
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis21
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer21
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis21
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer21
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women20
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer20
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape20
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer19
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer19
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor18
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence18
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer18
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy18
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women18
Subclonal heterogeneity and evolution in breast cancer17
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response17
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy17
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation17
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer17
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry17
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer17
Plasma C-peptide mammographic features and risk of breast cancer16
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study16
Post-diagnosis weight trajectories and mortality among women with breast cancer16
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention16
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer16
Artificial intelligence in breast pathology – dawn of a new era16
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer16
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer16
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study16
Racial discrimination among women seeking breast cancer care16
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression15
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial15
Advancing equitable access to innovation in breast cancer15
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination15
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer15
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts15
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer15
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer15
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics15
Genomic landscape of breast cancer in elderly patients15
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer14
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer14
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer14
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer14
MammOnc-DB, an integrative breast cancer data analysis platform for target discovery14
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings14
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer14
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study14
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer14
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study13
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer13
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy13
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials13
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer13
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment13
An emerging generation of endocrine therapies in breast cancer: a clinical perspective13
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials13
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers13
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients13
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy13
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer12
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function12
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade12
Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR12
Computerized cognitive training improves cognitive function in primary breast cancer survivors12
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer12
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools12
De-escalation in breast cancer surgery12
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management12
Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer12
Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation12
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden12
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning12
Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer12
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease12
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB11
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ11
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients11
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer11
Author Correction: Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis11
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes11
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning11
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer11
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study11
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer11
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab11
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial11
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition11
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers11
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study11
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer11
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer10
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis10
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial10
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling10
Allostatic load as a predictor of postoperative complications in patients with breast cancer10
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer10
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy10
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research10
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study10
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer10
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment10
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer10
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial10
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes10
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer10
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)10
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death10
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer10
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis10
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing9
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy9
CBD-oil as a potential solution in case of severe tamoxifen-related side effects9
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients9
Mammographic texture features associated with contralateral breast cancer in the WECARE Study9
Iminodibenzyl induced redirected COX-2 activity inhibits breast cancer progression9
Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America9
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study9
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer9
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer9
Immunotherapy in breast cancer: an overview of current strategies and perspectives9
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets8
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer8
Breast cancer dormancy is associated with a 4NG1 state and not senescence8
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy8
LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer8
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib8
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer8
The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue8
Predicting pathologic ≥N2 disease in women with breast cancer8
Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis8
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC8
Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer8
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer8
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer8
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models8
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies8
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)7
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study7
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ7
NR4A3 potentials M1-like macrophage polarization to facilitate anti-tumor immune responses in breast cancer7
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness7
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors7
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis7
Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer7
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer7
Altered ribosomal profile in acquired resistance and reversal associates with pathological response to chemotherapy in inflammatory breast cancer7
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer7
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets7
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial7
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype6
Integrative multiomics-histopathology analysis for breast cancer classification6
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer6
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial6
Performance of an AI-powered visualization software platform for precision surgery in breast cancer patients6
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification6
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 405026
Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer6
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients6
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study6
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer6
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing6
Circulating tumor cells in breast cancer: clinical validity and utility6
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)6
Reversion of breast epithelial polarity alterations caused by obesity6
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer6
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer6
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer6
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis6
0.067324161529541